Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)

被引：1

作者：

Aghajanian, C. ^{[1
]}

Blank, S. V. ^{[2
]}

Goff, B. ^{[3
]}

Judson, P. L. ^{[4
]}

Makhija, S. ^{[5
]}

Sharma, S. K. ^{[6
]}

Nycum, L. R. ^{[7
]}

Yi, J. ^{[8
]}

Husain, A. ^{[9
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Obstet & Gynecol, New York, NY 10021 USA

[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA

[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Ctr Womens Oncol, Tampa, FL 33612 USA

[5] Univ Louisville, Sch Med, Dept Obstet Gynecol & Womens Hlth, Louisville, KY 40292 USA

[6] Adventist Hinsdale Hosp, Obstet Gynecol, Hinsdale, IL USA

[7] Forsyth Reg Canc Ctr, Gynecol Oncol, Winston Salem, NC USA

[8] Genentech Inc, Biostat, San Francisco, CA 94080 USA

[9] Genentech Inc, BioOncol Dev, San Francisco, CA 94080 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(11)70104-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5LBA

引用

页码：5 / 5

页数：1